{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:20:24Z","timestamp":1790659224578,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Istanbul Ayd\u0131n University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Fibroblast growth factor-21 (FGF21) is a metabolic regulator involved in glucose and lipid homeostasis and has emerged as a potential biomarker in cardiometabolic diseases. The relationship between circulating FGF21 levels and coronary artery disease (CAD) remains unclear. We performed a systematic review and meta-analysis to clarify this association and assess its clinical relevance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Web of Science, and Scopus were searched for observational studies reporting circulating FGF21 levels in adult CAD patients. Standardized mean differences (SMDs) with 95% confidence intervals were calculated using a random-effects model. Subgroup and meta-regression analyses were conducted to explore heterogeneity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fourteen studies including 2963 CAD patients were analyzed. Circulating FGF21 levels were significantly higher in CAD patients than in controls (SMD\u2009=\u20090.90; 95% CI: 0.26\u20131.54;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0056). In acute CAD, the increase was more pronounced (SMD\u2009=\u20091.70; 95% CI: 0.20\u20133.21). Elevated FGF21 persisted even when diabetes prevalence was low (SMD\u2009=\u20091.50; 95% CI: 0.15\u20132.84). Meta-regression identified BMI and HDL as independent contributors to inter-study variability. Sensitivity analyses confirmed robustness, and no strong evidence of publication bias was detected.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Circulating FGF21 is elevated in CAD, primarily reflecting metabolic disturbances\u2014particularly adiposity and dyslipidemia\u2014rather than diabetes or CAD itself. Levels tend to be higher during acute events, suggesting that FGF21 may serve as a marker of metabolic stress and lipid abnormalities rather than a direct diagnostic biomarker.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11845-026-04472-2","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T02:01:04Z","timestamp":1780452064000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Circulating fibroblast growth factor-21 in coronary artery disease: a systematic review and meta-analysis"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5586-5893","authenticated-orcid":false,"given":"Feryal","family":"Shawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1113-7654","authenticated-orcid":false,"given":"Fatma","family":"Izzeddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9678-5652","authenticated-orcid":false,"given":"Gulsah","family":"Koc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"4472_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2991\/jegh.k.201217.001","volume":"11","author":"U Ralapanawa","year":"2021","unstructured":"Ralapanawa U, Sivakanesan R (2021) Epidemiology and the magnitude of coronary artery disease and acute coronary syndrome: a narrative review. J Epidemiol Glob Health 11:169. https:\/\/doi.org\/10.2991\/jegh.k.201217.001","journal-title":"J Epidemiol Glob Health"},{"key":"4472_CR2","doi-asserted-by":"publisher","first-page":"16812","DOI":"10.1002\/jcp.28350","volume":"234","author":"A Malakar","year":"2019","unstructured":"Malakar A, Choudhury D, Halder B et al (2019) A review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol 234:16812\u201316823. https:\/\/doi.org\/10.1002\/jcp.28350","journal-title":"J Cell Physiol"},{"key":"4472_CR3","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1097\/CM9.0000000000001890","volume":"134","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Liu D, Long X et al (2021) The role of FGF21 in the pathogenesis of cardiovascular disease. Chin Med J 134:2931\u20132943. https:\/\/doi.org\/10.1097\/CM9.0000000000001890","journal-title":"Chin Med J"},{"key":"4472_CR4","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/1540267","volume":"2016","author":"P Cheng","year":"2016","unstructured":"Cheng P, Zhang F, Yu L et al (2016) Physiological and pharmacological roles of FGF21 in cardiovascular diseases. J Diabetes Res 2016:1540267. https:\/\/doi.org\/10.1155\/2016\/1540267","journal-title":"J Diabetes Res"},{"key":"4472_CR5","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.jhep.2010.05.018","volume":"53","author":"H Li","year":"2010","unstructured":"Li H, Fang Q, Gao F et al (2010) Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol 53:934\u2013940. https:\/\/doi.org\/10.1016\/j.jhep.2010.05.018","journal-title":"J Hepatol"},{"key":"4472_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11684-013-0244-8","volume":"7","author":"H Li","year":"2013","unstructured":"Li H, Zhang J, Jia W (2013) Fibroblast growth factor 21: a novel metabolic regulator from pharmacology to physiology. Front Med 7:25\u201330. https:\/\/doi.org\/10.1007\/s11684-013-0244-8","journal-title":"Front Med"},{"key":"4472_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015534","volume":"5","author":"Z Lin","year":"2010","unstructured":"Lin Z, Wu Z, Yin X et al (2010) Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS One 5:e15534. https:\/\/doi.org\/10.1371\/journal.pone.0015534","journal-title":"PLoS One"},{"key":"4472_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-12-124","volume":"12","author":"Y Shen","year":"2013","unstructured":"Shen Y, Ma X, Zhou J et al (2013) Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease. Cardiovasc Diabetol 12:124. https:\/\/doi.org\/10.1186\/1475-2840-12-124","journal-title":"Cardiovasc Diabetol"},{"key":"4472_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.705273","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Yan J, Yang N et al (2021) High-level serum fibroblast growth factor 21 concentration \u0131s closely associated with an \u0131ncreased risk of cardiovascular diseases: a systematic review and meta-analysis. Front Cardiovasc Med. https:\/\/doi.org\/10.3389\/fcvm.2021.705273. 8;705273","journal-title":"Front Cardiovasc Med"},{"key":"4472_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/cen.12134","volume":"80","author":"Y Lee","year":"2014","unstructured":"Lee Y, Lim S, Hong E et al (2014) Serum FGF21 concentration is associated with hypertriglyceridaemia, hyperinsulinaemia and pericardial fat accumulation, independently of obesity, but not with current coronary artery status. Clin Endocrinol 80:57\u201364. https:\/\/doi.org\/10.1111\/cen.12134","journal-title":"Clin Endocrinol"},{"key":"4472_CR11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.atherosclerosis.2019.06.898","volume":"287","author":"KL Ong","year":"2019","unstructured":"Ong KL, Campbell S, Wu BJ et al (2019) Relationship of fibroblast growth factor 21 with subclinical atherosclerosis and cardiovascular events: Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 287:46\u201353. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.06.898","journal-title":"Atherosclerosis"},{"issue":"2","key":"4472_CR12","doi-asserted-by":"publisher","first-page":"162","DOI":"10.5937\/jomb0-30191","volume":"41","author":"G Nar","year":"2022","unstructured":"Nar G, Sanlialp S, Nar R et al (2022) Is serum fibroblast growth factor 21 associated with the severity or presence of coronary artery disease? J Med Biochem 41(2):162\u2013167. https:\/\/doi.org\/10.5937\/jomb0-30191","journal-title":"J Med Biochem"},{"key":"4472_CR13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.51924","volume":"16","author":"S Sinha","year":"2024","unstructured":"Sinha S, Prakash P, Keshari J et al (2024) The correlation between serum fibroblast growth factor 21 and the severity and occurrence of coronary artery disease. Cureus 16:e51924. https:\/\/doi.org\/10.7759\/cureus.51924","journal-title":"Cureus"},{"key":"4472_CR14","doi-asserted-by":"publisher","unstructured":"Page MJ, Moher D, Bossuyt PM et al (2021) PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews.\u00a0BMJ n160.\u00a0https:\/\/doi.org\/10.1136\/bmj.n160","DOI":"10.1136\/bmj.n160"},{"key":"4472_CR15","doi-asserted-by":"publisher","unstructured":"Palmeri V, Colamesta V, La Torre G (2016) Evaluation of methodological quality of studies. Senses Sci. https:\/\/doi.org\/10.14616\/sands-2016-3-235241","DOI":"10.14616\/sands-2016-3-235241"},{"key":"4472_CR16","unstructured":"Joanna Briggs Institute (2017) JBI critical appraisal checklist for analytical cross sectional studies. Joanna Briggs Institute, Adelaide"},{"key":"4472_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J et al (2014) Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol 14:135. https:\/\/doi.org\/10.1186\/1471-2288-14-135","journal-title":"BMC Med Res Methodol"},{"key":"4472_CR18","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.26355\/eurrev_202404_36016","volume":"28","author":"D Koprulu","year":"2024","unstructured":"Koprulu D, Toprak K, Genc Tapar G et al (2024) FGF-21: a novel biomarker predicting no-reflow in ST-segment elevation myocardial infarction. Eur Rev Med Pharmacol Sci 28:3024\u20133029. https:\/\/doi.org\/10.26355\/eurrev_202404_36016","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"4472_CR19","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20181099","volume":"38","author":"J Cheng","year":"2018","unstructured":"Cheng J, Su X, Qiao L et al (2018) Circulating level of fibroblast growth factor 21 is independently associated with the risks of unstable angina pectoris. Biosci Rep 38:BSR20181099. https:\/\/doi.org\/10.1042\/BSR20181099","journal-title":"Biosci Rep"},{"key":"4472_CR20","unstructured":"Higgins JT, Eldridge S, Li T (2024) Chap. 23: Including variants on randomized trials. In:Cochrane handbook for systematic reviews of interventions. Cochrane. https:\/\/www.cochrane.org\/handbook"},{"key":"4472_CR21","first-page":"9625","volume":"9","author":"H Chen","year":"2016","unstructured":"Chen H, Wu F, Lu N et al (2016) Decreased levels of serum fibroblast growth factor 21 in Chinese patients with coronary artery disease. Int J Clin Exp Pathol 9:9625\u20139630","journal-title":"Int J Clin Exp Pathol"},{"key":"4472_CR22","first-page":"2958","volume":"10","author":"H Chen","year":"2018","unstructured":"Chen H, Lu N, Zheng M (2018) A high circulating FGF21 level as a prognostic marker in patients with acute myocardial infarction. Am J Transl Res 10:2958\u20132966","journal-title":"Am J Transl Res"},{"key":"4472_CR23","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3346\/jkms.2015.30.5.586","volume":"30","author":"W Kim","year":"2015","unstructured":"Kim W, Kim S, Lee H et al (2015) Association between serum fibroblast growth factor 21 and coronary artery disease in patients with type 2 diabetes. J Korean Med Sci 30:586\u2013590. https:\/\/doi.org\/10.3346\/jkms.2015.30.5.586","journal-title":"J Korean Med Sci"},{"key":"4472_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2024.156591","volume":"178","author":"X Liu","year":"2024","unstructured":"Liu X, Dong M, Li T et al (2024) Correlation of circulating fibroblast growth factor 21 levels with inflammatory factors and the degree of coronary artery stenosis in patients with acute myocardial infarction. Cytokine 178:156591. https:\/\/doi.org\/10.1016\/j.cyto.2024.156591","journal-title":"Cytokine"},{"key":"4472_CR25","doi-asserted-by":"publisher","first-page":"821","DOI":"10.5551\/jat.41731","volume":"25","author":"Y Miyazaki","year":"2018","unstructured":"Miyazaki Y, Saita E, Kishimoto Y et al (2018) Low plasma levels of fibroblast growth factor-21 in patients with peripheral artery disease. J Atheroscler Thromb 25:821\u2013828. https:\/\/doi.org\/10.5551\/jat.41731","journal-title":"J Atheroscler Thromb"},{"key":"4472_CR26","doi-asserted-by":"publisher","DOI":"10.13201\/j.issn.1001-1439.2022.10.007","author":"S QIAN","year":"2022","unstructured":"QIAN S, LI M, YAO Z et al (2022) Correlation between serum FGF21, CHOP levels, and acute coronary syndrome and its clinical prognosis. J Clin Cardiol. https:\/\/doi.org\/10.13201\/j.issn.1001-1439.2022.10.007. 38.","journal-title":"J Clin Cardiol"},{"key":"4472_CR27","doi-asserted-by":"publisher","first-page":"122","DOI":"10.13201\/j.issn.1001-1439.2024.02.008","volume":"40","author":"J Zhang","year":"2024","unstructured":"Zhang J, Xiao H, Sun Q et al (2024) Correlation analysis of serum FGF21 level and myocardial fibrosis in patient with acute myocardial infarction and its influence on long-term prognosis. J Clin Cardiol 40:122\u2013127. https:\/\/doi.org\/10.13201\/j.issn.1001-1439.2024.02.008","journal-title":"J Clin Cardiol"},{"key":"4472_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1108234","volume":"14","author":"B Yan","year":"2023","unstructured":"Yan B, Ma S, Yan C et al (2023) Fibroblast growth factor 21 and prognosis of patients with cardiovascular disease: a meta-analysis. Front Endocrinol 14. https:\/\/doi.org\/10.3389\/fendo.2023.1108234","journal-title":"Front Endocrinol"},{"key":"4472_CR29","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.clnu.2016.04.027","volume":"36","author":"J G\u00f3mez-Ambrosi","year":"2017","unstructured":"G\u00f3mez-Ambrosi J, Gallego-Escuredo JM, Catal\u00e1n V et al (2017) FGF19 and FGF21 serum concentrations in human obesity and type 2 diabetes behave differently after diet- or surgically-induced weight loss. Clin Nutr 36:861\u2013868. https:\/\/doi.org\/10.1016\/j.clnu.2016.04.027","journal-title":"Clin Nutr"},{"key":"4472_CR30","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1210\/me.2010-0142","volume":"24","author":"K Fon Tacer","year":"2010","unstructured":"Fon Tacer K, Bookout AL, Ding X et al (2010) Comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol 24:2050\u20132064. https:\/\/doi.org\/10.1210\/me.2010-0142","journal-title":"Mol Endocrinol"},{"key":"4472_CR31","doi-asserted-by":"publisher","first-page":"R13","DOI":"10.1530\/JOE-15-0289","volume":"227","author":"P Tanajak","year":"2015","unstructured":"Tanajak P, Chattipakorn S, Chattipakorn N (2015) Effects of fibroblast growth factor 21 on the heart. J Endocrinol 227:R13\u2013R30. https:\/\/doi.org\/10.1530\/JOE-15-0289","journal-title":"J Endocrinol"},{"key":"4472_CR32","doi-asserted-by":"publisher","first-page":"66","DOI":"10.7150\/ijbs.73936","volume":"19","author":"H Tan","year":"2023","unstructured":"Tan H, Yue T, Chen Z et al (2023) Targeting FGF21 in cardiovascular and metabolic diseases: from mechanism to medicine. Int J Biol Sci 19:66\u201388. https:\/\/doi.org\/10.7150\/ijbs.73936","journal-title":"Int J Biol Sci"},{"key":"4472_CR33","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.cca.2017.07.017","volume":"472","author":"J Wang","year":"2017","unstructured":"Wang J, Sheu W, Lee W et al (2017) Associations of fibroblast growth factor 21 with cardiovascular risk and \u03b2-cell function in patients who had no history of diabetes. Clin Chim Acta 472:80\u201385. https:\/\/doi.org\/10.1016\/j.cca.2017.07.017","journal-title":"Clin Chim Acta"},{"key":"4472_CR34","doi-asserted-by":"publisher","first-page":"4886","DOI":"10.1210\/jc.2016-2308","volume":"101","author":"Q Li","year":"2016","unstructured":"Li Q, Zhang Y, Ding D et al (2016) Association between serum fibroblast growth factor 21 and mortality among patients with coronary artery disease. J Clin Endocrinol Metab 101:4886\u20134894. https:\/\/doi.org\/10.1210\/jc.2016-2308","journal-title":"J Clin Endocrinol Metab"},{"key":"4472_CR35","doi-asserted-by":"publisher","first-page":"28","DOI":"10.2152\/jmi.61.28","volume":"61","author":"Q-R Jin","year":"2014","unstructured":"Jin Q-R, Bando Y, Miyawaki K, Shikama Y, Kosugi C et al (2014) Correlation of fibroblast growth factor 21 serum levels with metabolic parameters in Japanese subjects. J Med Invest 61:28\u201334. https:\/\/doi.org\/10.2152\/jmi.61.28","journal-title":"J Med Invest"},{"key":"4472_CR36","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/4024877","volume":"2023","author":"K Gawlik","year":"2023","unstructured":"Gawlik K, Milewicz T, Pawlica-Gosiewska D, Trznadel-Morawska I et al (2023) Fibroblast growth factor 21 in gestational diabetes mellitus and type 2 diabetes mellitus. J Diabetes Res 2023:4024877. https:\/\/doi.org\/10.1155\/2023\/4024877","journal-title":"J Diabetes Res"},{"key":"4472_CR37","unstructured":"Shahjehan RD, Sharma S, Bhutta BS (2026) Coronary artery disease. StatPearls. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK564304\/"},{"key":"4472_CR38","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.12235","volume":"9","author":"L Gu","year":"2021","unstructured":"Gu L, Jiang W, Qian H et al (2021) Elevated serum FGF21 predicts the major adverse cardiovascular events in STEMI patients after emergency percutaneous coronary intervention. PeerJ 9:e12235. https:\/\/doi.org\/10.7717\/peerj.12235","journal-title":"PeerJ"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-026-04472-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-026-04472-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-026-04472-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T02:01:08Z","timestamp":1780452068000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-026-04472-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":38,"alternative-id":["4472"],"URL":"https:\/\/doi.org\/10.1007\/s11845-026-04472-2","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"14 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The author(s) declared no potential conflicts of interest with respect to the research, authorship and\/or publication of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}